Novartis (Symbol: NVS) has been named to the Dividend Channel ”International S.A.F.E. 10” list, signifying an international stock with above-average ”DividendRank”statistics including a strong 3.2% yield, as well as a superb track record of at least five years of dividend growth, according to the most recent ”DividendRank” report.
According to the ETF Finder at ETF Channel , Novartis is an underlying holding representing 1.45% of the Powershares International Dividend Achievers ETF ( PID ), which holds $12,345,394 worth of NVS shares. Novartis (Symbol: NVS) made the “Dividend Channel International S.A.F.E. 10” list because of these qualities: S . Solid return – hefty yield and strong DividendRank characteristics; A. Accelerating amount – consistent dividend increases over time; F . Flawless five year history – never a missed or lowered dividend; E. Enduring – at least a half-decade of dividend payments.
The annualized dividend paid by Novartis is $2.75/share, currently paid in annual installments, and its most recent dividend ex-date was on 03/01/2017.
NVS operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson ( JNJ), and Pfizer Inc ( PFE ).
Source: Nasdaq
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
